Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
Bianca Santomasso, Loretta J. Nastoupil, Sherry Adkins, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 35, pp. 3978-3992
Open Access | Times Cited: 118

Showing 1-25 of 118 citing articles:

Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results
Stephen Bagley, Meghan Logun, Joseph A. Fraietta, et al.
Nature Medicine (2024) Vol. 30, Iss. 5, pp. 1320-1329
Closed Access | Times Cited: 113
How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy
Michael D. Jain, Melody Smith, Nirali N. Shah
Blood (2023)
Open Access | Times Cited: 85
Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem
Naman Sharma, Patrick M. Reagan, Jane L. Liesveld
Cancers (2022) Vol. 14, Iss. 6, pp. 1501-1501
Open Access | Times Cited: 78
Advancing CAR T cell therapy through the use of multidimensional omics data
Jingwen Yang, Yamei Chen, Ying Jing, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 211-228
Closed Access | Times Cited: 65
The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)
Bita Shakoory, Ashley V. Geerlinks, Marta Wilejto, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 10, pp. 1271-1285
Open Access | Times Cited: 62
Current understanding and management of CAR T cell-associated toxicities
Jennifer N. Brudno, James N. Kochenderfer
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 501-521
Closed Access | Times Cited: 60
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Lu Tang, Zhongpei Huang, Heng Mei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 59
Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future
Sarah A. Holstein, Shakira J. Grant, Tanya M. Wildes
Journal of Clinical Oncology (2023) Vol. 41, Iss. 27, pp. 4416-4429
Open Access | Times Cited: 46
Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Deep Shah, Brian W. Soper, Lindsay S. Shopland
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 45
Novel strategies to manage CAR-T cell toxicity
Arthur Mulvey, Lionel Trueb, George Coukos, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 4
Cancer vaccines: platforms and current progress
Wanting Lei, Kexun Zhou, Ye Lei, et al.
Molecular Biomedicine (2025) Vol. 6, Iss. 1
Open Access | Times Cited: 2
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Md. Mominur Rahman, Tapan Behl, Md. Rezaul Islam, et al.
Molecules (2022) Vol. 27, Iss. 12, pp. 3798-3798
Open Access | Times Cited: 44
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19
Caroline Diorio, Rawan Shraim, Regina M. Myers, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 17, pp. 3804-3813
Open Access | Times Cited: 44
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
Kevin C. Miller, P. Connor Johnson, Jeremy S. Abramson, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 10
Open Access | Times Cited: 44
Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma
Jessica S Little, Muneerah M Aleissa, Katherine Beluch, et al.
Blood Advances (2022) Vol. 6, Iss. 16, pp. 4821-4830
Open Access | Times Cited: 43
Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
Rakesh Awasthi, Harald J. Maier, Jie Zhang, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 40
How I treat unique and difficult to manage cases of CAR T-cell therapy associated neurotoxicity
Bianca Santomasso, Juliane Gust, Fabiana Perna
Blood (2023)
Open Access | Times Cited: 39
Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome
Tim Lakomy, Dilara Akhoundova, Henning Nilius, et al.
Biomolecules (2023) Vol. 13, Iss. 2, pp. 382-382
Open Access | Times Cited: 32
Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
Dilara Akhoundova, Katja Seipel, Ulrike Bacher, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 28
CAR-T cell therapy: Where are we now, and where are we heading?
Jiayi Wang, Liang Wang
Blood Science (2023) Vol. 5, Iss. 4, pp. 237-248
Open Access | Times Cited: 28
Anti‐CLL1 ‐based CAR T ‐cells with 4‐1‐BB or CD28 / CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia
Kunlin Pei, Haoyu Xu, Pengfei Wang, et al.
Cancer Medicine (2023) Vol. 12, Iss. 8, pp. 9655-9661
Open Access | Times Cited: 23
The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention
Jessica S Little, Eleftheria Kampouri, Daniel Friedman, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 6
Open Access | Times Cited: 14
Mechanisms and management of CAR T toxicity
Christopher Ferreri, Manisha Bhutani
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 14
The next frontier in immunotherapy: potential and challenges of CAR-macrophages
Jing Li, Ping Chen, Wenxue Ma
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Andrew D Hughes, David T. Teachey, Caroline Diorio
Seminars in Immunopathology (2024) Vol. 46, Iss. 3-4
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top